EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Home‐Based Tele‐tDCS in Amyotrophic Lateral Sclerosis: Feasibility, Safety, and Preliminary Efficacy

Sangeetha Madhavan, Shravni Deshmukh iD, Mark Cummings, Aditi Doshi, Kourosh Rezania, Sally Freels, Gina Sawa

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70038 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Sangeetha Madhavan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Brain Plasticity Laboratory, Department of Physical Therapy, College of Applied Health Sciences, University of Illinois Chicago, Chicago, Illinois, U…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Transcranial Direct Current Stimulation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited treatment options. Transcranial direct current stimulation (tDCS) shows promise as a neuromodulatory intervention in various neurological disorders, but its application in ALS, particularly in a remote, home‐based format, remains underexplored. This study investigates the feasibility, safety, and preliminary efficacy of remotely supervised tele‐tDCS in ALS patients.

Methods

This double‐blinded pilot study included 14 spinal‐onset ALS participants randomized into two groups: the intervention group received 72 tele‐tDCS sessions over 24 weeks, and the delayed‐start group received 36 sham sessions followed by 36 tele‐tDCS sessions. Stimulation was delivered at 2 mA for 20 min 3 times a week. Primary outcomes included feasibility, safety, and disease progression measured by the ALS Functional Rating Scale‐Revised (ALSFRS‐R). Adherence and adverse effects were monitored throughout.

Results

Ten participants completed the study, with an overall compliance rate of 98.3%. No serious adverse events were reported, and mild side effects, like itching and tingling, were consistent with tDCS literature. The intervention group demonstrated a significantly slower decline in ALSFRS‐R scores than the delayed‐start group. At 24 weeks, the intervention group had a mean ALSFRS‐R change of −1.7, compared to −13.6 in the delayed‐start group ( p = 0.0018). Additionally, the change in ALSFRS‐R between pre‐ and mid‐intervention significantly differed between groups ( p = 0.0071).

Interpretation

Tele‐tDCS was feasible, safe, and well‐tolerated in individuals with ALS. Preliminary efficacy results suggest that tele‐tDCS may slow disease progression, underscoring the potential of tele‐tDCS as a promising home‐based neuromodulatory intervention in ALS management. Trial Registration: Clinical trial registration: NCT04866771

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisTranscranial Direct Current StimulationHumansFemaleMaleMiddle AgedPilot ProjectsDouble-Blind MethodFeasibility StudiesAgedTelemedicineAdultDisease ProgressionTreatment Outcome

Stichwörter der Autor:innen

amyotrophic lateral sclerosisdisease progressionneurodegenerative diseasesneuromodulationtranscranial direct current stimulation (tDCS)

Autor:innen und Institutionen

  • Brain Plasticity Laboratory, Department of Physical Therapy, College of Applied Health Sciences, University of Illinois Chicago, Chicago, Illinois, USA.
  • Graduate Program in Rehabilitation Science, College of Applied Health Sciences, University of Illinois Chicago, Chicago, Illinois, USA.
  • Graduate Program in Neuroscience, University of Illinois Chicago, Chicago, Illinois, USA.
  • Biological Sciences Division, Department of Neurology, University of Chicago, Chicago, Illinois, USA.
  • Department of Epidemiology and Biostatistics, School of Public Health, University of Illinois Chicago, Chicago, Illinois, USA.

ORCID-Profile: Shravni Deshmukh

Förderung

  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Madhavan, S., Deshmukh, S., Cummings, M., Doshi, A., Rezania, K., Freels, S., & Sawa, G. (2025). Home‐Based Tele‐tDCS in Amyotrophic Lateral Sclerosis: Feasibility, Safety, and Preliminary Efficacy. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70038

Vancouver

Madhavan S, Deshmukh S, Cummings M, Doshi A, Rezania K, Freels S, et al. Home‐Based Tele‐tDCS in Amyotrophic Lateral Sclerosis: Feasibility, Safety, and Preliminary Efficacy. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70038

BibTeX
@article{Madhavan2025,
  author = {Madhavan, Sangeetha and Deshmukh, Shravni and Cummings, Mark and Doshi, Aditi and Rezania, Kourosh and Freels, Sally and Sawa, Gina},
  title = {Home‐Based Tele‐tDCS in Amyotrophic Lateral Sclerosis: Feasibility, Safety, and Preliminary Efficacy},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70038}
}
Kostenlos starten →